# US 2023/0055321 A1 · Pyrimidopyrrole spiro compounds and derivatives thereof as dna-pk inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0055321 A1
- Document ID: US20230055321A1
- Status: Published application
- Kind: A1
- Application number: 17/778,533
- Filed: 2020-11-20
- Published: 2023-02-23
- Earliest claimed: 2019-11-22
- Assignees: Medshine Discovery Inc.
- Applicants: Medshine Discovery Inc.
- Inventors: Kevin X CHEN; Shanghua XIA; Zhaoguo CHEN; Zuhao GUO; Yanxin YU; Kai ZHOU; Boyu HU; Li ZHANG; Fen JIANG; Jingjing WANG; Guoping HU; Jian LI; Shuhui CHEN
- Web page: https://patentgrep.com/patent/US20230055321A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 35/00: Antineoplastic agents
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/02: specific for leukemia
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided are a class of DNA-PK inhibitor, and specifically, a compound represented by formula (III) or a pharmaceutically acceptable salt thereof, and use thereof in the preparation of DNA-PK inhibitor-related drugs.

## Claims

### Claim 1

A compound represented by formula (III) or a pharmaceutically acceptable salt thereof,
wherein,
R5 and R6 combining with the carbon atoms to which they are attached form
when is a single bond, E1 is selected from —O—, —S—, —C(═O)—, —S(═O)2—, —C(R1)(R2)—, —N(R3)— and
when is a double bond, E1 is selected from —C(R1—;
R1and R2 are each independently selected from H, OH, F, CI, Br, I, C1-3 alkoxy and C1-3 alkyl, and the C1-3 alkoxy and C1-3 alkyl are optionally substituted by 1, 2 or 3 Ra;
or, R1and R2 combining with the carbon atoms to which they are attached form a cyclopropyl, cyclobutyl and oxetanyl;
R3 is selected from C1-3 alkyl-C(═O)— and C1-3 alkyl, and the C1-3 alkyl-C(═O)— and C1-3 alkyl are optionally substituted by 1, 2 or 3 Rb;
R4 is selected from C1-3 alkoxy;
n is selected from 0, 1 and 2, provided that when E1 is selected from —C(R1)(R2)—, and both R1 and R2 are selected from H, n is not 0;
m is selected from 1, 2 and 3;
X1, X2, X3, X4 and X5 are each independently selected from N, C and CH, provided that at most three of X1, X2, X3, X4 and X5 are N, and the ring formed with X1, X2, X3, X4 and X5 is an aromatic ring;
X6 is selected from CH and N;
Y1 is selected from F, CI, Br, I, cyclopropyl and C1-3 alkyl, and the C1-3 alkyl is optionally substituted by OH or 1, 2 or 3 Ra;
Y2 is selected from cyclopropyl and C1-3 alkyl, and the C1-3 alkyl is optionally substituted by 1, 2, 3, 4 or 5 F;
Ra and Rb are each independently selected from H, F, Cl, Br, I.

### Claim 2 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, the compound represented by formula (III) or the pharmaceutically acceptable salt thereof is selected from a compound represented by formula (III-1), or a command represented by formula (III-2) or a pharmaceutically acceptable salt thereof,
wherein, X1, X2, X3, X4, X5, X6, Y1, Y2, E1 n and m are as defined above.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, X1, X3 and X4 are selected from N, X2 is selected from CH, X5 is selected from C, and X6 is selected from CH and N; or, X1, X2 and X4 are selected from N, X3 is selected from CH, X5 is selected from C, X6 is selected from CH; or, X1, X3 and X5 are selected from N, X2 is selected from CH, X4 is selected from C, and X6 is selected from CH; or, X1 and X4 are selected from N, X2 and X3 are selected from CH, X5 is selected from C, X6 is selected from CH and N.

### Claim 5 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, Y1 is selected from F, Cl, cyclopropyl, CH3, CH2OH, CFH2, CF2H and CF3; Y2 is selected from cyclopropyl, CH3, CFH2, CF2H and CF3.

### Claim 6 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, the compound represented by formula (III) or the pharmaceutically acceptable salt thereof is selected from a compound represented by formula (I) or a pharmaceutically acceptable salt thereof,
wherein, E1 and n are as defined above.

### Claim 7 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof as claimed in claim 1, selecting from a compound represented by formula (II) or a pharmaceutically acceptable salt thereof,
wherein, m is as defined above.

### Claim 8 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, is a single bond, E1 is selected from —O—, —S—, —C(═O)—, —S(O)2—, —C(R1)(R2)—, —N(R3)— and
and R1, R2, R3 and R4 are as defined above.

### Claim 9 (depends on 8)

The compound or the pharmaceutically acceptable salt thereof as claimed in claim 8, wherein, is a single bond, E1 is selected from —O—, —C(R1)(R2)—, —N(R3)— and
and R1, R2, R3 and R4 are as defined above.

### Claim 10 (depends on 8)

The compound or the pharmaceutically acceptable salt thereof as claimed in claim 8, wherein, R1 and R2 are each independently selected from H, OH, F, Cl, C1-3 alkoxy and C1-3 alkyl, and the C1-3 alkoxy and C1-3 alkyl are optionally substituted by 1,2 or 3 H or F; R3 is selected from C1-3 alkyl-C(═O)— and C1-3 alkyl, and the C1-3 alkyl-C(═O)— and C1-3 alkyl are optionally substituted by 1,2 or 3 H or F; R4 is selected from C1-3 alkoxy.

### Claim 11 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, is a double bond, E1 is selected from —C(R1)—, R1is selected from H, F, Cl, Br, I, C1-3 alkoxy and C1-3 alkyl, and the C1-3 alkoxy and C1-3 alkyl are optionally substituted by 1, 2 or 3 Ra, and Ra is as defined above.

### Claim 12 (depends on 11)

The compound or the pharmaceutically acceptable salt thereof as claimed in claim 11, wherein, is a double bond, E1 is selected from —C(R1)—, R1is selected from H, F, C1-3 alkyl, and the C1-3 alkyl is optionally substituted by 1, 2 or 3 H or F.

### Claim 13 (depends on 8)

The compound or the pharmaceutically acceptable salt thereof as claimed in claim 8, wherein, R1and R2 are each independently selected from H, OH, F, CH3, CF3 and CH3O—.

### Claim 14 (depends on 8)

The compound or the pharmaceutically acceptable salt thereof as claimed in claim 8, wherein, R1and R2 combining with the carbon atoms to which they are attached form
or R3 is selected from CH3, CH3CH2 and CH3C(═O)—, and the CH3, CH3CH2 and CH3C(═O)— are optionally substituted by 1, 2 or 3 Rb, and Rb is as defined above;
or, R4 is selected from CH3O—.

### Claim 15

(canceled)

### Claim 16 (depends on 14)

The compound or the pharmaceutically acceptable salt thereof as claimed in claim 14, wherein, R3 is selected from CH3, CF3CH2 and CH3C(═O)—.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, the structural moiety
is selected from
and R1, R2, R3 and R4 are as defined above.

### Claim 19 (depends on 18)

The compound or the pharmaceutically acceptable salt thereof as claimed in claim 18, wherein, the structural moiety
is selected from

### Claim 20 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof as claimed in claim 1, and the compound is selected from
wherein, E1, R1, R2, R3 and R4 are as defined above.

### Claim 21

A compound represented by the following formula or a pharmaceutically acceptable salt thereof

### Claim 22 (depends on 1)

A method of inhibiting DNA-PK in a subject in need thereof, comprising administering the compound or the pharmaceutically acceptable salt thereof as claimed in claim 1 into the subject.

### Claim 23 (depends on 22)

The method as claimed in claim 22, wherein, the compound or the pharmaceutically acceptable salt therof plays a therapeutic effect as a single medicament in tumors with defects in other DNA repair pathways;
or, the compound or the pharmaceutically acceptable salt thereof is used in combination with chemoradiotherapy medicaments to enhance the inhibitory effect on solid tumors and hematological tumors.

### Claim 24

(canceled)
